logo-loader
bit bio

Full interview: Bit bio developing a technology platform 'capable of producing any human cell type'

Bit bio's Mark Kotter speaks to Proactive London's Andrew Scott following the name change from Elpis Biomed.

The business has recently hired a number of industry heavy-hitters to its leadership team as it works towards its goal of developing a scalable platform technology capable of producing any human cell type.

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of bit bio named herein, including the promotion by the Company of bit bio in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Elpis Biomed thrilled to be crowned 'Start-up Of The Year' at tech awards

Elpis Biomed's Dr Mark Kotter spoke to Proactive London's Andrew Scott after being voted the 2018 Cambridge Start-Up of the Year. Elpis is developing high quality human cells via its proprietary OPTi-OX platform. Kotter also discusses their fundraise which they're in the middle of. He...

on 21/11/18

2 min read